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ABSTRACT
Purpose: Urokinase-like Plasminogen Activator Receptor (uPAR) is overexpressed 
in a variety of carcinoma types, and therefore represents an attractive imaging target. 
The aim of this study was to assess the feasibility of two uPAR-targeted probes for 
PET and fluorescence tumor imaging in a human xenograft tongue cancer model.
Experimental design and results: Tumor growth of tongue cancer was 
monitored by bioluminescence imaging (BLI) and MRI. Either ICG-Glu-Glu-AE105 
(fluorescent agent) or 64Cu-DOTA-AE105 (PET agent) was injected systemically, and 
fluorescence imaging or PET/CT imaging was performed. Tissue was collected for 
micro-fluorescence imaging and histology. A clear fluorescent signal was detected in 
the primary tumor with a mean in vivo tumor-to-background ratio of 2.5. Real-time 
fluorescence-guided tumor resection was possible, and sub-millimeter tumor deposits 
could be localized. Histological analysis showed co-localization of the fluorescent 
signal, uPAR expression and tumor deposits. In addition, the feasibility of uPAR-
guided robotic cancer surgery was demonstrated. Also, uPAR-PET imaging showed a 
clear and localized signal in the tongue tumors.
Conclusions: This study demonstrated the feasibility of combining two uPAR-
targeted probes in a preclinical head and neck cancer model. The PET modality 
provided preoperative non-invasive tumor imaging and the optical modality allowed 
for real-time fluorescence-guided tumor detection and resection. Clinical translation 
of this platform seems promising.
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) 
ranked the 6th most frequent cancer globally in 2013 
with more than 800.000 new cases and 360.000 deaths 
reported annually [1]. In oncological surgery the 
fundamental principle is complete removal of all cancer 
tissue to achieve cure. An intended radical procedure 
has to be balanced against sparing of healthy tissue to 
maintain an acceptable functional and cosmetic outcome 
which is especially important in the head and neck 
region due to anatomical complexity and presence of 
important neurovascular structures. In most solid cancer 
types, including HNSCC, positive surgical margins are 
associated with an increased local recurrence-rate and 
poor survival outcome and therefore remains a major 
challenge [2; 3]. The rate of inadequate resection margins, 
defined as involved or close (<5 mm), in oral squamous 
cell carcinoma (OSCC) ranged from 30-85% in recent 
published series [4].
Preoperative imaging modalities (CT, MRI, PET, 
ultrasound) for staging and planning provide information 
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about tumor location and extension, but current 
modalities lack sufficient resolution to detect microscopic 
(subclinical) disease [5; 6]. As a consequence the surgeon 
intraoperatively still relies on visual inspection and 
palpation of the tissues to assess tumor borders. Histology 
of frozen sections is widely used intraoperatively for 
margin assessment, but the technique is time consuming 
and is essentially a sampling technique that fails to 
represent the entire tumor mass and is therefore less 
accurate compared to postoperative histology workup [7]. 
Accordingly, there is an unmet need for novel modalities 
that allows for accurate intraoperative delineation of 
tumors form healthy tissue to guide tumor resection with 
clear margins.
Optical near-infrared (NIR) imaging is an emerging 
technology that enables real-time imaging of injected 
fluorescent molecular agents accumulated in tissues or 
structures using dedicated camera systems designed for 
intraoperative use. Indocyanine Green (ICG) is one of the 
few clinically approved fluorophores in the NIR spectrum 
with favorable optical-chemical properties and safety 
profile [8]. Currently, ICG-based fluorescence imaging 
has proved clinically feasible for sentinel node biopsy 
for OSCC and many other malignancies, by our group 
and by others, where the agent is exploited in a purely 
non-targeted manner for lymph node detection [9; 10]. 
The development of fluorescent probes targeted against 
tumor-specific biomarkers has expanded the research in 
optical imaging and this may lead to a paradigm shift in 
oncological surgery. Tumor-targeted fluorescent probes 
may provide an enhanced contrast between neoplastic 
and healthy tissue and thereby be an intraoperative tool 
to guide tumor resection with safe margins and to detect 
residual disease in the surgical bed [11].
The urokinase-like Plasminogen Activator Receptor 
(uPAR) system plays a key role in tumor invasion, 
angiogenesis and metastasis, and high uPAR expression 
has been reported in many types of carcinoma, including 
HNSCC [12]. Elevated uPAR activity has consistently 
been associated with tumor aggressiveness and shown 
to be a prognostic biomarker for reduced local tumor 
control and survival outcome, e.g. in OSCC and breast 
cancer [13; 14]. Importantly, uPAR is located on the cell 
surface and is regarded tumor-specific because of low 
or insignificant expression in homeostatic human tissues 
and is therefore an interesting biomarker for targeted 
imaging or therapy [15]. The nona-mer peptide AE105 
has been described as a ligand with nano-molar affinity 
for uPAR and has served as a platform in our group and 
by others, to develop preclinical AE105-based molecular 
conjugations for tumor-specific PET imaging and therapy 
[16–20]. A clinical phase-1 study on uPAR-PET using 
64Cu-DOTA-AE105 in patients with breast, bladder and 
prostate cancers was recently published by our group 
with promising results [21]. To explore the translational 
potential of uPAR-targeted optical imaging we recently 
reported the applicability of a conjugate of ICG and AE105 
(ICG-Glu-Glu-AE105) in a preclinical subcutaneous 
tumor model [22]. The probe showed high uPAR affinity, 
plasma stability and favorable optical properties in vitro, 
and in vivo tumor-specific binding during real-time 
fluorescence imaging was demonstrated. Consequently, 
the purpose of this study was to explore the feasibility 
of combined uPAR-targeted PET and NIR fluorescence 
imaging for tumor detection and NIR fluorescence-guided 
tumor resection in an orthotopic human xenograft model 
of tongue cancer.
RESULTS
In vitro uPAR expression of the OSCC cell line
Results from flow cytometry showed a clear right-
shift of the fluorescent signal compared to control cells 
thus demonstrating high level of uPAR expression on 
OSC-19-luc2 cells in vitro (Figure 1c).
NIRF imaging and tumor-specificity of ICG-Glu-
Glu-AE105
In study 1 animals that had OSC-19-luc2 cells 
implanted (n=8) developed a rapidly growing tongue 
tumor with metastatic spread to first an ipsilateral followed 
by bilateral neck lymph nodes (n=7) monitored by BLI 
(Figure 2). Neck metastases were present on day 3 or 
day 10 in animals inoculated with 105 or 104 tumor cells, 
respectively. These findings indicate, that the temporal 
progression of the metastatic process depends on the initial 
tumor burden in the orthotopic animal model and thus 
recapitulate the clinical nature of HNSCC. The mean size 
of the tongue tumors measured on histology sections in 
study 1 was 4.0 mm (range 3.4-5.2 mm) in the high-dose 
inoculation group and 2.3 mm (range 1.4-3.5 mm) in the 
low dose inoculation group and showed involvement of a 
substantial part of the mobile tongue.
After administration of ICG-Glu-Glu-AE105 
optical imaging 12 h post-injection showed a clear and 
well demarked signal in the tongue of tumor-bearing mice, 
while no localized signal could be seen in control animals 
(n=8) in vivo. In all animals injected with the optical probe 
a weak fluorescent signal could be seen universally in 
the skin and around the nose region. The mean TBR in 
vivo was 2.5 +/- 0.2 using the preclinical IVIS scanner, 
and 2.3 +/- 0.1 with the clinical camera system, and 
significantly higher with both systems compared to 
control animals (p <0.001) (Figure 1D). After the animals 
were sacrificed and the neck was entered, lymph node 
metastases were not recognizable while dissecting under 
bright light illumination, but could only be detected using 
NIR fluorescence imaging guidance. The lymph node 
metastases were located in the submandibular region 
often covered by salivary gland tissue, and the intensity of 
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the fluorescence signal was highly depended on exposure 
reflecting attenuation of light photons in biological tissue. 
The intraoperative and ex vivo TBRs for detection of tumor 
and lymph node metastasis were 3.0 +/- 0.3 and 2.2 +/- 0.1 
respectively (Figure 2). Histological analysis of adjacent 
tissue sections stained for H&E and CK confirmed the 
presence of a poorly differentiated invasive OSCC in the 
resected tongues and metastatic deposits in the lymph 
nodes identified by optical imaging. Furthermore, IHC 
staining for uPAR showed a homogenous expression in 
the primary tumors and metastasis with staining of the cell 
membrane primarily. Micro-NIR fluorescence imaging of 
tissue sections showed co-localization of the fluorescence 
signal and the presence of tumor compared to non-cancer 
tissues demonstrating tumor-specific binding of ICG-Glu-
Glu-AE105 (Figure 3). In one animal a tongue tumor was 
intentionally resected exactly along the contrast border 
created by the fluorescence signal, and a sub-millimeter 
residual deposit in the tongue base observed by optical 
imaging was confirmed to be tumor tissue on histology 
(Figure 4 and Supplementary Video 1).
Detection threshold of ICG-Glu-Glu-AE105 and 
MR Imaging for monitoring tumor growth
By using a longitudinal design in study 2 a cohort 
of animals with a wide range of sizes of primary tongue 
tumors was established. The maximal diameter of the 
tumors ranged from 75-2.350 μm measured on histology 
sections. On MRI the lower threshold for detection was 
150 μm, and in animals where serial MRI was performed 
over time, the individual tumor growth could accurately be 
visualized (Supplementary Figure 1). Measurement of the 
tumor size in histology sections and on MRI was highly 
significantly correlated (p < 0.0001, r = 0.99). On in vivo 
NIRF imaging the smallest detectable tumor was 400 μm 
Figure 1: Chemical structure of imaging agents and tumor-target specificity: The chemical structure of 64Cu-DOTA-
AE105 for uPAR-PET A. and and ICG-Glu-Glu-AE105 for optical imaging B. Both agents were designed using the nona-mer 
peptide AE105 as a scafhold to ensure high binding afffinity to uPAR. Using flowcytometry expression of uPAR on OSC-19-luc2 cells 
was confirmed C. Blank buffer (red), secondary antibody only (green), isotype control antibody + secondary antibody (blue), anti-uPAR 
antibody + secondary antibody (yellow). Box plot comparing the mean intensity of the fluorescent signal, expressed as TBR, in control 
animals without tumor and animals bearing a tongue tumor D.
Oncotarget15410www.impactjournals.com/oncotarget
Figure 2: NIRF imaging: Representative imaging captured from one animal. Imaging of a tongue tumor in vivo a, e, i. and ex 
vivo b, f, j. The neck was entered ex vivo with a midline incision from the chest to the jaw and the jaw was resected to expose the base and 
mobile part of the tongue. The tongue specimen and the bilateral lymph node metastases identified and dissected guided by optical guidance 
c, g, k. Preoperatively the presence of tumor and neck metastases was confirmed by BLI d. and compared to intraoperative findings with 
NIRF imaging h, l. An example of real-time optical tumor imaging with clinical Fluobeam®800 camera system are demonstrated in 
supplementary data as a video recording.
Figure 3: Micro-NIRF imaging and tumor-specificity: Fluorescence imaging of adjacent tissue sections of a large tongue 
tumor A. and a lymph node with a tumor deposit located in the subcapsular sinus B. subsequently stained for H&E and 
uPAR. In the tongue specimen local spread of tumor nests in the stroma below the mucosa along to entire inferior aspect of the tongue was 
noted. In the tongue and the lymph node co-localization of the fluorescent signal and the presence of tumor was seen. An example of real-time 
tumor resection along the demarcation line created by the fluorescent signal where tissue with a clear signal deliberately was left behind in the 
base of the tongue C. On the corresponding histology from the base of tongue residual disease was identified in the inferior part of the tongue 
which corresponded to the findings on macroscopic and micro-NIRF imaging. The scale bars on the H&E stainings represents 1000 μm.
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in maximal diameter, while tumors below this threshold 
had a blurred signal and reliable tumor demarcation was 
not possible. With the assumptions of a mean diameter of 
the cancer cells of 10 μm, an approximate cell volume of 
1 pL and a spherical tumor shape, the cellular detection 
threshold was 6 x 104 cells. However, when the tongues 
were transected ex vivo, the intensity of the fluorescence 
signal increased, and the demarcation line against 
surrounding normal tissue was sharpened. The mean 
TBR in study 2 in vivo was 1.7 (range 1.3-2.4) in the 
preclinical IVIS scanner and 1.6 (range 1.1-2.3) with the 
clinical NIRF camera. As proof of concept, NIRF-guided 
tumor-resection of small lateralized tongue tumors was 
performed in a subset of the animals (Figure 5). In two 
animals additional fluorescence imaging and real-time 
robotic tumor dissection with the da Vinci robot system 
was performed. A demarked fluorescence signal in the 
tongue tumors could be detected and alternate use of the 
optical and the color imaging functions to visualize tumor 
while dissecting the tissue was possible (Figure 6 and 
Supplementary Video 2).
In vivo uPAR-PET and FDG-PET
After injection of either 18F-FDG or 64Cu-DOTA-
AE105 (N=4) a clear and localized PET signal could be 
seen in the tongue tumors on PET/CT imaging (Figure 
4). The mean TBR measured as SUV max was 2.14 +/- 
0.20 for FDG-PET and 2.65 +/- 0.41 for uPAR-PET.The 
smallest tumor enrolled in the PET protocol had a maximal 
diameter of 1.66 mm that corresponds to aproximately 2 x 
106 cells detected. The tumors could not be deliniated on 
CT, and were only indentifiable when combined with the 
PET modality. Lymph node neck metastases could not be 
detected by any of the two PET tracer agents.
DISCUSSION
Our results provide the first evidence for feasibility 
of intraoperative use of an uPAR-directed NIR fluorescent 
agent imaging for in vivo detection and delineation 
of HNSCC. A sufficient contrast between tumor and 
healthy tissue could be achieved, and the agent showed 
evidence of tumor-specific binding on macroscopic and 
microscopic NIR imaging. The observation, that very 
small pre-neoangiogenic sized tumor deposits co-localized 
with the fluorescent signal on micro-NIR imaging was a 
strong argument for tumor-specificity that makes it very 
unlikely, that the non-targeted enhanced-permeability 
and retention (EPR)-effect could be responsible for our 
findings. In addition, we have provided solid evidence 
for uPAR-specific interaction of ICG-Glu-Glu-AE105 
in a previous publication [22]. As proof of concept, the 
potential synergistic power of combining uPAR targeted 
non-invasive preoperative PET imaging for planning of 
surgery and intraoperative optical-guided tumor resection 
was also demonstrated.
For planning a targeted imaging strategy in a specific 
type of cancer, essentially the target has to be expressed, 
and with a high positive expression-rate across a cohort 
of patients to be of relevance. Target availability within a 
tumor, expressed as receptor density on the cellular level, 
is positively correlated with the TBR from an injected 
imaging agent. Accordingly, our group has previously 
published preclinical data showing that uPAR-PET can 
Figure 4: Multimodality imaging: Same animal with a 1.66 millimeter large tumor in the left anterior tongue subjected 
to 18FDG-PET a, b. uPAR-PET f, g. BLI c. MRI d, e. white arrow marking tumor) and uPAR NIRF imaging h. in vivo. 
Tissue section stained for H&E i. where scale bar represents 1000 μm.
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Figure 5: Fluorescence-guided tumor resection: Same animal with a 1.31 mm large tumor in the left anterior tongue as 
shown on preoperative MRI (a, b, white arrow marking tumor). A time sequence of NIRF imaging where the tongue was fixed 
with a suture in the tip of the tongue and tumor resection with a small curved scissor was performed guided by real-time optical imaging 
f-i. On histology the tongue specimen showed a clear resection margin, while the resection specimen showed a localized tumor surrounded 
by healthy tissue showing radicality of the tumor excision.(c, e).
Figure 6: Fluorescence-guided robotic tumor imaging and dissection: Imaging from the same animal with a large 
tumor in the anterior tongue and bilateral neck metastasis as seen on BLI. d. Fluorescence in vivo imaging performed with 
the Fluobeam®800 camera system a. and combined fluorescence and color ex vivo imaging using the da Vinci®Si™ surgical robot b, e. 
A delineated fluorescence signal from the tumor underlying the mucosa was detected by both NIR camera systems. After transection of 
the anterior tongue in the midline using the robot a tumor was seen on the resection surface (white arrow) on color imaging c. and the 
tumor margins could be outlined guided by the fluorescence function in the robot f. Briefly the da Vinci® Si™ surgical robot has three 
maneuverable arms for instruments and a maneuverable HD 3D camera, all operated by the surgeon placed in a separate console. Real-time 
video of the surgical field is presented for the surgeon either as 3D color video or 3D fluorescence imaging. Instant switching between the 
two modalities is possible to maintain a steady workflow while an accurate dissection is performed.
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be used quantitatively to measure uPAR tumor expression 
[19]. In that way uPAR PET can be used as a non-invasive 
biopsy, and as opposed to a surgical biopsy sample, uPAR 
PET enables assessment of uPAR expression in the entire 
tumor volume. Given, that uPAR expression is prognostic 
for survival outcome in a range of cancers, uPAR PET may 
potentially be used for risk assessment of cancer patients 
and to tailor treatment. In relation to uPAR-targeted 
optical-guided surgery, we believe preoperative uPAR-
PET will be of benefit to determine if a tumor is suitable 
for an optical-guided approach. Both to determine if the 
tumor is positive for uPAR, and to assess the level of uPAR 
expression in the entire tumor compartment. It should be 
noted that with uPAR-PET it is possible to quantify the 
level of tracer uptake and thereby the receptor density. 
The relationship between the level of target expression and 
the magnitude of TBR that can be achieved in biological 
tissues using injected targeted optical agents is still to be 
determined. Theoretically, low target expression (receptor 
density) may result in inadequately low TBR for reliable 
intraoperative optical margin assessment. However, the 
detected TBR from an optical agent is influenced by other 
factors, most importantly the sensitivity of the applied 
camera system and the clearance of unbound imaging 
agent in surrounding normal tissue. The fully investigate 
the impact of tumor receptor density on detected signal 
intensity for an optical agent will require data from a study 
in a series of cancer patients. We believe that a uPAR-PET 
based cut-off value for uptake may be established above 
which the optical probe will deliver sufficient contrast to 
guide surgery.
Key factors for successful clinical translation of 
optical-guided oncologic surgery are the development of 
agents with a high tumor-binding specificity conjugated 
to a clinically relevant fluorophore in the NIR spectrum, 
with sufficient brightness to ensure adequate contrast 
between diseased and healthy tissue. The activation of 
the plasminogen system in the process of cancer invasion 
in numerous types of carcinomas makes uPAR a highly 
relevant target for therapeutic/theranostic purposes. 
To our knowledge, this study is the first to investigate 
uPAR-targeted optical imaging in head and neck cancer. 
Targeting uPAR with fluorescent probes with various 
targeting molecules and fluorescent ligands has been 
explored in a few other preclinical animal studies in mice. 
Similar to our approach Sun and colleagues recently 
described the labeling of AE105 with Cy5.5 and optical 
imaging of subcutaneous flank tumors [23]. Antibodies 
against uPAR labeled with Alexa Flour 680 or Cy5.5 were 
used for imaging in prostate, breast and pancreas cancer 
animal models [24; 25]. Boonstra and coworkers recently 
published convincing data of optical imaging in colorectal 
tumor models using an anti-uPAR antibody conjugated to 
the newly introduced fluorophore ZW800-1 [26]. Another 
logical strategy has been to label the amino-terminal-
fragment (ATF) of uPA, the natural ligand of uPAR. In 
one study ATF was labeled with a phthalocynine derivate 
(CPZ) for imaging in a hepatoma model and Yang and 
colleagues investigated ATF conjugations to Cy5.5 or 
NIR-830 for optical imaging in animals bearing breast 
tumors [27; 28]. However, in the above-mentioned studies 
the fluorophores have never been used in humans, and only 
ZW800-1 was reported to have passed the first steps for 
clinical approval. In contrast, ICG is approved for clinical 
use by FDA and EMA, and the existing clinical data on 
ICG is substantial, which may offer an advantage in the 
regulatory process of clinical translation of ICG-Glu-
Glu-AE105. Further, all the existing NIR camera systems 
approved for intraoperative clinical use are optimized for 
imaging of ICG because non-conjugated ICG already has 
several clinical applications, e.g. imaging of bile ducts, 
ureters, renal flow, flap reconstruction and sentinel node 
biopsy [29].
The development of clinical NIR camera systems 
that can be readily integrated in a surgical procedure and 
provide high resolution optical imaging is evenly crucial 
for the clinical translation of optical-guided surgery [30]. 
In the present study a clinical camera system designed 
for open surgery procedures (Fluobeam®800) was used, 
and to further emphasize the translational potential of the 
technology, fluorescence-guided surgery using a surgical 
robot (da Vinci®Si™) was demonstrated. In HNSCC 
transoral robotic surgery (TORS) is developing rapidly 
and allows surgeons to resect tumors that previously were 
technically surgically inaccessible without performing a 
major surgical invasive procedure [31; 32]. In that context 
the additional use of cancers-specific optical agents 
in conjunction with a robotic device to enable accurate 
image-guided cancer surgery seems very promising and 
warrants further exploration.
Compared to other imaging modalities, optical 
imaging may provide detection of very small tumor 
volumes in the sub-millimeter range, but the clinical 
detection threshold for cancer tissue for this modality 
is still to be determined. In a translational perspective, 
the lower limit for tumor detection for optical imaging 
agents is important to examine, if the modality is to be 
used either for detection of residual disease in the tumor 
bed after resection, or to identify small solitary metastatic 
deposits in disseminated cancer. It is generally accepted, 
that a TBR > 2 is required to ensure sufficient contrast 
for reliable optical imaging [33]. The purpose of study 
2 was to explore the minimal size of a tumor deposit 
needed to enable optical tumor detection with ICG-Glu-
Glu-AE105. The smallest tumor detected was 400 μm, 
and generally the TBRs were lower in study 2 compared 
to study 1, where larger tumors were studied (mean TBR 
1.7 vs. 2.5). Light photons have a limited penetration in 
biological tissues, and the signal intensity depends on the 
amount of tracer retained in the tissue, and thereby the 
size of the tumor deposit. In the orthotopic tongue cancer 
model we used in the current study, human carcinoma 
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cells were implanted below the mucosa of the tongue, and 
during growth the tumors remained embedded within the 
tongue muscle without the development of an epithelial 
lesion. In this way the model did not fully imitate the 
clinical situation of human HNSCC originating from the 
epithelium. The carcinoma is known to be present in the 
surface throughout the course of tumor growth. In study 
2 the majority of the tumor deposits were located 2-3 
millimeters below the mucosa, and this may explain the 
moderate TBRs observed. Because of tissue attenuation 
the true tumor detection threshold may be lower if surface-
involving tumor lesions were studied. Importantly for the 
further translation of fluorescence-guided surgery in to the 
clinic, some exposure of the cancer-invaded tissue seems 
to be necessary, especially if the modality is exploited for 
detection of small solitary tumor deposits. Importantly, the 
lymph node metastases in the neck of the animals only 
could be identified by optical guidance. However, some 
exposure by surgical dissection of tissue was necessary 
to detect deeply located metastasis by fluorescence 
guidance. We anticipate that for clinical use, also some 
dissection of overlying tissues would be needed to provide 
adequate penetrance of NIR photons to enable optical 
guidance towards nodal metastatic deposits in the neck. 
Accordingly, optical-guided surgery seems suited for easy 
integration in the neck dissection procedure, which is 
the standard principle for surgical management of neck 
metastasis in HNSCC.
In a future clinical scenario of optical-guided 
tumor resection, for example in the oral cavity, optical 
assessment of the deep margin may be challenged by 
sup-optimal visual access with the camera system, 
bleeding and coagulated tissue after electro-cauterization 
for hemostasis. Adequate design of the camera system 
to access different regions and cavities of the body is 
of paramount importance. We hypothesize, that optical 
imaging of the tumor bed intraoperatively after completed 
tumor resection to detect small sub-millimeter tumor 
deposits in the margin will be of great importance. Also 
direct optical imaging of the entire resection surface of the 
tumor specimen in the operation room will be of relevance 
to detected an involved margin and allow for immediate 
resection of additional tissue in the tumor bed.
Because HNSCC often is accessible for open 
resection transorally due to direct visualization of the 
transformed mucosal line in the upper aerodigestive 
tract, it is very suitable for an optical imaging approach. 
In preclinical animal models of head and neck cancer, 
optical imaging agents targeted against αvβ3 integrin [34], 
cathepsine B, metalloproteinases [16], PARP1 [35], and 
Figure 7: Study design: In study 1 A. animals in the control group and in the high dose inoculation group were 
sacrificed on day 12 while animals in the low dose inoculation group were sacrificed on day 19. In study 2 B. 2-4 animals 
were sacrificed every 2.-4. day and the last animals were sacrificed on day 17.
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EGFR [36] have been investigated. In a recent study, 
Rosenthal and colleagues published first-in-man results on 
safety of an EFGR-targeted optical probe in 12 HNSCC 
patients [37]. Apart from expression in many types of 
carcinomas, the plasminogen activator system seems 
unique because uPAR not only is expressed by tumor cells, 
but also by tumor-associated stromal cells and immune 
cells in the tumor microenvironment. This expression 
pattern enables simultaneous molecular targeting of both 
the tumor and the stromal compartment, which may be an 
advantage for imaging and intervention purposes because 
of high receptor density in the entire tumor volume [38]. 
Most HNSCC is characterized by a marked desmoplastic 
reaction within the tumor and at the invasive border and 
therefore has a substantial stromal component which can 
be exploited in a uPAR-targeted theranostic strategy [39].
BLI based on genetically transfected tumor cell 
lines with the luciferase gene is a highly useful tool in 
preclinical animal cancer research for tumor detection 
and monitoring of tumor growth, but the modality is not 
clinically applicable. For estimation of the exact tumor 
volume BLI is also less accurate, and in the present study 
the use of MR imaging for exact temporal monitoring of 
tumor size was demonstrated. In addition, a high magnetic 
field strength of 7 Tesla enabled high-resolution imaging 
of tumor-related anatomy and a very low threshold for 
tumor detection (150 μm). High resolution MR imaging 
of internally located tumors in animal models offers novel 
possibilities in animal research, and is directly comparable 
to clinical oncology, where MR imaging is increasingly 
used. In the perspective of molecular imaging the fusion of 
targeted PET tracers, like uPAR-PET, with MRI may have 
future important implications due to improved anatomical 
imaging of the targeted tissue structures as reported 
recently by our group [40].
In the present study tumor detection could be 
achieved equally with both FDG- and uPAR-PET. 
However, the targeting mechanisms for the two PET 
ligands are very different. FDG-PET is based on imaging 
of glucose metabolism via the glucose-transporter 
GLUT1, while uPAR-PET is targeted against uPAR, 
which is a biomarker specific to cancer and associated 
with invasion. Even though FDG-PET is extensively used 
in clinical oncology, there are well known limitations 
due to enhanced glucose metabolism in different non-
malignant tissues, and a limited detection threshold for 
small cancer deposits. Accordingly, FDG-PET currently 
has very limited role to play in staging of HNSCC due 
to insufficient diagnostic performance [41]. In contrast, 
uPAR-PET may offer highly tumor-specific imaging 
as recently demonstrated in a first-in-man study by our 
group, which could have several implications in staging, 
risk-stratification, patient-selection and post-treatment 
surveillance [21]. By adding optical imaging to a uPAR-
targeted strategy we demonstrated bridging of the gap 
between preoperative uPAR-PET imaging for tumor 
assessment and planning, and intraoperative optical 
guidance for tumor detection, delineation and resection, 
based on ligands with an identical binding domain directed 
against the same oncotarget. When targeted preoperative 
and intraoperative imaging is closely linked, the additional 
information may facilitate chances for effective radical 
surgery of tumor and metastasis.
In conclusion this study demonstrated the feasibility 
of real-time fluorescence-guided accurate tumor detection 
and resection in a preclinical head and neck cancer model 
using the uPAR-targeted ligand ICG-Glu-Glu-AE105. 
Further we showed the powerful rational of combing 
preoperative uPAR-PET and intraoperative uPAR-directed 
optical guidance to plan and perform surgical tumor 
intervention. Clinical validation trials of uPAR-targeted 
optical imaging are warranted.
MATERIALS AND METHODS
Animal study design
Two animal studies were performed to address 
different research questions (Figure 7). Study 1 was 
designed to investigate the tumor target specificity, non-
specific uptake in healthy tissue and fluorescence intensity 
of ICG-Glu-Glu-AE105. Study 2 was designed to examine 
tumor detection threshold of the agent, proof of concept of 
optical-guided tumor resection, tumor growth monitored 
by MRI and performance of 64Cu-DOTA-AE105 for 
uPAR-PET in the tongue cancer model. The preparation 
and characterization of ICG-Glu-Glu-AE105 and 64Cu-
DOTA-AE105 has been published previously [19; 22]. 
The chemical structure of the two imaging agents is 
depicted in Figure 1 (panel A and B).
Cell line and Orthotopic xenograft animal model
The human OSCC metastatic cell line OSC-19-luc2 
(kindly provided by prof. J.N. Myers, M.D. Anderson 
Cancer Center, Texas, USA) was cultured in Dulbecco’s 
modified medium (Life Technologies, Paisly, UK), 
supplemented with 10% fetal bovine serum (FBS), 1% 
Pen-strep, 1% Sodium Pyruvate and 1% Non-essential 
amino acid stored at 37°C in a 5% CO2 incubator. Female 
6 weeks old NMRI nude mice were obtained (Taconic 
Europe, Denmark) and housed in an experimental animal 
facility at the University of Copenhagen on a 12 h day/
night cycle with food and water available ad libitum. All 
animal studies were carried out with the approval by the 
Animal Research Committee of the Danish Ministry of 
Justice (2014-15-0201-00099). Animals were monitored 
regularly for weight loss and general health deterioration 
and euthanized by cervical dislocation. An orthotopic 
tongue cancer model was established by injection of 104 
or 105 OSC-19-luc2 cells suspended in 15 microliter PBS 
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buffer with a 29 G needle in the left anterior tongue under 
4% sevoflurane anaesthesia. Cell Injection was performed 
either in free hand (study 1) or with a controlled micro 
pump system (PHD 2000 Infusion/withdraw, Harvard 
Apparatus Inc., Massachusetts, USA) to achieve minimal 
hydrostatic injection pressure and accurate tumor 
implantation (study 2).
Flow cytometry
Flow cytometry was applied to examine uPAR 
expression on OSC-19-luc2 cells. Cells were grown to 
70-80% confluence and harvested with 10 nM EDTA and 
washed in PBS buffer. Cells were stained with Viability 
Dye (eBioscience, Califonia, USA) and stained with an in-
house produced anti-uPAR antibody (Finsen Laboratory, 
Copenhagen, Denmark), an irrelevant IgG isotype matched 
control antibody (bs-0295P Bioss, Woburn, MA, USA) or 
blank buffer control for 30 min in 4°C. Secondary staining 
was performed with an allophycocyanin (APC) conjugated 
detection antibody (sc-3846, Santa Cruz, Heidelberg, 
Germany) for 30 min in 4°C. The result were analysed 
on a BD FACSCanto™ II (BD Biosciences, California, 
USA).
Optical imaging
Bioluminescence imaging (BLI) was applied to 
monitor tumor growth exploiting the luciferase enzyme 
inserted in the cell line used. Animals were given an 
intraperitoneal injection of 150 μL Luciferin (150 mg/
mL) (PerkinElmer, Massachusetts, USA), and 10 min 
post-injection imaging was performed with the IVIS 
Lumina XR system and for image processing the 
acquisition software Living Image was used (PerkinElmer, 
Massachusetts, USA). The BLI signal was quantified by 
the total photon flux (photons/sec) in regions of interest 
(ROIs) of the tumor and neck metastasis.
For fluorescence imaging animals were given a tail 
vein injection of 10 nmol ICG-Glu-Glu-AE105 followed 
by optical imaging 6-15 h post-injection. The optimal 
time-window was characterized in a previous study and 
found to be 6-24 h post-injection [22]. First fluorescence 
imaging was performed in the preclinical system IVIS 
Lumina XR with the excitation filter at 745 nm and the 
emission filter set for ICG. Next animals were transferred 
to a surgical table for imaging with the clinically approved 
NIR-camera system Fluobeam®800 (Fluoptics, Grenoble, 
France). The hand-held camera head was mounted on a 
surgical arm to allow for hands-free surgical procedures 
during real-time imaging. This system is customized for 
ICG imaging working with an 800 nm excitation laser 
and has a 16x optical zoom and functions for image and 
video recordings. In vivo imaging was followed by ex vivo 
imaging, and surgical procedures were performed. In two 
animals in study 2 additional fluorescence imaging and 
tumor dissection was performed with a clinically approved 
surgical robot system using non-human instruments 
(Da Vinci® Si™, Intuitive Surgical, California, USA). 
Animals were anaesthetized with 2% isoflurane before and 
during all in vivo imaging procedures.
In vivo fluorescence intensity was quantified as 
tumor-to-background-ratio (TBR) calculated as a ROI 
over the tongue divided by a standard background ROI 
placed over the chest region. In a similar way an ex vivo 
(intraoperative) TBR was calculated by drawing a standard 
background ROI over adjacent muscle tissue. Images 
from the IVIS Lumina XR and the Fluobeam®800 were 
processed in Living Image and the ImageJ software (1.46r, 
NIH, USA) respectively.
MR and PET imaging
MR imaging was performed on a 7 tesla small 
animal scanner (Biospec 7.0, Bruker BioSpin, Ettlingen, 
Germany). A Turbo-Rare high-resolution T2-weighted 
protocol was applied to generate sagittal and axial imaging 
of the head region. The slide thickness was 0.3 mm and 11 
slides were acquired for each orientation. The echo time 
was 20 ms and the repetition time was 1200 ms. The field 
of view was 19 x 16 mm with an image size of 120 x120 
mm and the read out spatial resolution was 0.158 mm. The 
accompanying ParaVision 6.0 software (Bruker Biospin) 
was used for data analysis.
PET scans were acquired in a 10 min static protocol 
with a microPET Focus 120 scanner (Siemens Medical 
Solutions, Erlangen, Germany) 4 hours post i.v. injection 
of a mean of 8.2 (range 7.5-8.9) MBq 64Cu-DOTA-AE105 
or 1 hour post i.v. injection of a mean of 9.3 (range 6.9-
11.0) MBq 18F-FDG during 4% Sevofluran anesthesia. 
Tracer preparations and PET/CT settings were used as 
described in a previous paper from our group [19]. All 
data were analyzed using Inveon Software (Siemens 
Medical Solutions) and tumor signal was expressed as 
TBR calculated from measurement of SUV max in ROIs 
in tumor and adjacent tongue muscle.
Histology and NIRF tissue imaging
In study 1 resected tongues were bisected and either 
snap frozen in liquid nitrogen or fixated in alcohol and 
embedded in paraffin. Next 8 μm frozen tissue sections 
and 4 μm paraffin-embedded sections were prepared, and 
micro-NIR fluorescence imaging in the Odyssey Scanner 
(LI-COR Biosciences, Nebraska, USA) was obtained. In 
study 2 fixated and paraffin-embedded tissue blocks from 
tongues were step-sectioned at levels of 50-100 μm to 
obtain 4 μm sections with the greatest extension of tumor 
tissue. Adjacent tissue sections were subsequently stained 
for either hematoxylin and eosin (H&E), cytokeratin (CK; 
rabbit-anti-cow cytokeratin WAA 1:500, z0622, Dako, 
Glostrup, Denmark) or uPAR (rabbit-anti-human uPAR, 
Oncotarget15417www.impactjournals.com/oncotarget
1:100, Finsen Laboratory, Copenhagen, Denmark). Stained 
sections were scanned to create digital images, and size of 
tumor deposits was measured in the accompanying Zenn 
lite software (Axio Scan.Z1, Carl Zeiss, Jena, Germany). 
Merging of micro-NIR images and digital images of the 
same sections was done in the Corel Paintshop Pro X5 
software (Corel Corporation, USA).
Statistical analysis
The SAS software package (SAS Institute Inc., 
version 6.1, USA) was used. Quantitative data were 
described as mean +/- SEM or range, and groups were 
compared using a student t-test. For correlation analysis 
Pearsons test was applied. A p-value of 0.05 was 
considered significant.
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